HOME > word lists > Clinical Trial Acronyms: M to Z

word lists

Clinical Trial Acronyms: M to Z

• MADIT: multicenter automatic defibrillator implantation trial
• MAGIC: magnesium in coronay arteries
• MARISA: monotherapy assessment of ranolazine in stable angina; MT Desk glossary
• MARRVEL: magnetic resonance radionuclide ventriculography and echocardiography in left ventricular function
• MARVAL: microalbuminuria reduction with valsartan [Diovan®]
• MASH: magnesium and acetylsalicylic acid in subarachnoid hemorrhage
• MATCH: management of atherothrombosis with clopidogrel [Plavix™] in high-risk patients with recent transient ischemic attack or ischemic stroke
• MDC: metoprolol in dilated cardiomyopathy
• MDPIT: multicenter diltiazem post infarction trial
• MEDENOX: prophylaxis in medical patients with enoxaparin [Lovenox®]
• MERIT-HF: metoprolol CR/XL (controlled release) randomized intervention trial in heart failure; MT Desk glossary
• MIAMI: Multi-Link® Duet™ coronary stent in acute myocardial infarction
• MICRO-HOPE: microalbuminuria, cardiovascular, and renal outcomes (HOPE [heart outcomes prevention evaluation] substudy)
• MIRA: minocycline in rheumatoid arthritis
• MIRACL: myocardial ischemia reduction with aggressive cholesterol lowering
• MIRACLE: multicenter InSync™ randomized clinical evaluation (North America)
• MIRACLE ICD: multicenter InSync™ randomized clinical evaluation implantable cardioverter defibrillator
• MIRAGE: multi-institutional research in Alzheimer genetic epidemiology
• MMAIT: malignant melanoma active immunotherapy trials; [Canvaxin™]
• MMSS: MyoVive™ marketing surveillance study; MT Desk glossary
• MOBILE: more patency with beta for in-stent restenosis in the lower extremity; sponsor: Novoste Corporation [Corona™ system]
• MOCHA: multicenter oral carvedilol [Coreg®] heart failure assessment
• MONICA: monitoring trends and determinants in cardiovascular disease
• MORE: multiple outcomes of raloxifene evaluation
• MOST: mode selection trial in sinus node dysfunction
• MOXCON: moxonidine congestive heart failure trial; MT Desk glossary
• MRFIT: multiple risk factor intervention trial
• MR IMAGES: magnetic resonance in intravenous magnesium efficacy in stroke
• MSMI: multicenter study of myocardial ischemia
• MUST:
  • medication use studies; MT Desk glossary
  • multicenter stent study; MT Desk glossary
  • multicenter stents ticlopidine; MT Desk glossary
• MUST EECP: multicenter study of enhanced external counterpulsation [EECP®]
• MUSTIC: multisite stimulation in cardiomyopathy
• MUSTT: multicenter unstable tachycardia trial; MT Desk glossary
  multicenter unsustained tachycardia trial; MT Desk glossary
• NAFT: North American Fragmin® trial
• NASCET: North American symptomatic carotid endarterectomy trial; MT Desk glossary
• NAVIGATOR: nateglinide and valsartan in impaired glucose tolerance outcomes research; MT Desk glossary
• NETT: national emphysema treatment trial
• NETWORK: Network of general practitioners and hospital physicians involved in the study of low versus high doses of enalapril in patients with heart failure trial
• NICE: Novacor® inflow conduit evaluation; sponsor: World Heart Corporation
• NICE 3: national investigators collaborating on enoxaparin [Lovenox®]
• NOCIS: new onset Crohn's intervention study
• OASIS / OASIS-2: organization to assess strategies for ischemic syndromes
• OAT: open artery trial
• OBJECT: overactive bladder: judging effective control and treatment [Ditropan XL v. Detrol]
• OCBAS: optimal coronary balloon angioplasty versus stent
• OCTAVE: omapatrilat [Vanlev™] cardiovascular treatment assessment versus enalapril
• OHTS: ocular hypertension treatment study
• OMNIUM: omeprazole [Prilosec®] versus misoprostol [Cytotec®] for NSAID-induced ulcer management
• ONTARGET: ongoing telmisartan [Micardis®] alone and in combination with ramipril [Altace®] global endpoint trial
• OPERA: omapatrilat [Vanlev™] in persons with enhanced risk of atherosclerotic events; MT Desk glossary
• OPTIC: optimal pharmacological therapy in implantable cardioverter defibrillator patients; sponsor: St. Jude Medical
• OPTIMAAL: optimal trial in myocardial infarction with the angiotensin II antagonist losartan
• OPTIME-CHF: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure
• OPUS: orbofiban in patients with unstable coronary syndromes
• ORBIT: oral glycoprotein IIb/IIIa receptor blockade to inhibit thrombosis; MT Desk glossary
• OVERTURE: omapatrilat versus enalapril randomized trial of utility in reducing events; MT Desk glossary
• PAC-A-TACH: pacing in atrial fibrillation and tachycardia
• PACIFIC: potential angina class improvement for intramyocardial channels
• PACT:
  • Philadelphia Association of Clinical Trials study
  • plasminogen activator angioplasty compatibility trial
  • prehospital application of coronary thrombolysis
  • prourokinase in acute coronary thrombosis
• PAMI: primary angioplasty in acute myocardial infarction; MT Desk glossary
• PARADIGM: pramlintide for amylin replacement adjunct for diabetes in glycemic management; MT Desk glossary
• PARAGON: platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in the global organization network
• PARIS: peripheral artery radiation investigational study [study of the Nucletron® Paris® leg artery radiation catheter]
• PASS II: piracetam acute stroke study II search help: piracetam
• PATH-CHF: pacing therapies for congestive heart failure
• PAVE: post AV node ablation evaluation; sponsored by St. Jude Medical
• PCDD: prevention of cardiovascular disease in diabetes
• PCI-CURE: clopidogrel [Plavix®] in unstable angina to prevent recurrent ischemic events in patients undergoing percutaneous coronary intervention; companion to CURE study
• PCPT: prostate cancer prevention trial; information
• PDQUALIF: Parkinson('s) disease quality of life
• PEACE: prevention of events with angiotensin converting enzyme [ACE] inhibitor therapy
• PEECH™: prospective evaluation of EECP® in congestive heart failure; sponsor, Vasomedical, Inc.
• PENTALYSE: synthetic pentasaccharide as an adjunct to fibrinolysis in ST-elevation acute myocardial infarction
• PENTUA: pentasaccharide in unstable angina
• PEPI: postmenopausal estrogen/progestin interventions study
• PETHEMA: programa para el estudio y tratamiento de las hemopatías malignas [program for the study and treatment of malignant hemopathies]
• PHADE: pneumatic HeartMate® assist as destination evaluation; MT Desk glossary
• PHAROS: pilot Huntington at risk observational study
• PIE: protease inhibitor experienced [study of Fortovase™ with Kaletra™]
• PIVOT: prostate cancer intervention versus observation trial
• PLESS: Proscar® long-term efficacy and safety study; MT Desk glossary
• PLUS: propentofylline long-term use study
• POEM: patency, outcomes and economics of MIDCAB; MT Desk glossary
• POLAR: pilot study of low-temperature angiogenic revascularization; sponsor: CryoCath Technologies, Inc.
• POST:
  • posterior stroke trial
  • potassium-channel opening stroke trial
• POWER: PTH for osteoporotic women on estrogen replacement [ALX1-11, a recombinant parathyroid hormone (PTH) formulation]; sponsor: NPS Pharmaceuticals
• PRAGUE: primary angioplasty in patients transferred from general community hospitals to specialized PTCA units with or without emergency thrombolysis
• PRAISE: prospective randomized amlodipine survival evaluation
• PRECEDENT: prospective randomized ectopy evaluation on dobutamine or Natrecor® (nesiritide) therapy; Scios Inc.
• PREDICT-HD: neurobiologic predictors of Huntington disease onset
• PREFER: preference study of Gengraf™ compared to Neoral™ in stable solid organ transplant subjects
• PREPARE: prevent postmenopausal Alzheimer's with replacement estrogens (a.k.a. Alzheimer('s) disease prevention trial)
• PRESENT: preliminary safety evaluation of nanoporous tacrolimus-eluting stents; sponsor: JOMED N.V.
• PRESTO:
  • Parkinson('s) rasagiline: efficacy & safety in the treatment of "OFF"
  • prevention of restenosis with tranilast and its outcomes
• PREVENT:
  • prevention of recurrent venous thromboembolism
  • program in ex vivo vein graft engineering via transfection
  • proliferation reduction with vascular energy trial; sponsor: Guidant Corp.
  • prospective randomized evaluation of the vascular effects of Norvasc® trial
• PRIDE: protection during saphenous vein graft intervention to prevent distal embolization); MT Desk glossary
• PRIME:
  • pramipexole in minority persons with Parkinson('s) disease: efficacy
  • program for irbesartan mortality and morbidity evaluations [consists of two studies: IRMA 2 and IDNT]
• PRIMO-CABG: pexelizumab for reduction in infarction and mortality in coronary artery bypass graft surgery
• PRINCE: pravastatin inflammation/CRP evaluation
• PRINCESS: prevention of reinfarction with early treatment by cerivastatin study
• PRISM-PLUS: platelet receptor inhibition for ischemic syndrome management in patients limited to very unstable signs and symptoms; MT Desk glossary
• PROACT: prolyse in acute cerebral thromboembolism
• PROACTION: prospective randomized outcomes study of acutely decompensated congestive heart failure treated initially in outpatients with Natrecor®; MT Desk glossary
• PROBE: Primacor (milrinone lactate) for optimization of beta-blocker efficacy
• PROBE evaluation: prospective, randomized, open, blinded endpoint; MT Desk glossary
• PROBIT: promotion of breastfeeding intervention trial
• PROGENI: Parkinson('s) research: the organized genetics initiative
• PROGRESS: perindopril [Aceon®] protection against recurrent stroke study
• PROMPT: profiling Remicade onset with methotrexate in a prospective trial
• PROSPER: prospective study of pravastatin in the elderly at risk
• PROTEKT: prospective resistant organism tracking for the ketolide telithromycin [Ketek™]
• PROVE IT: pravastatin or atorvastatin evaluation and infection therapy; MT Desk glossary
• PROWESS: recombinant human activated protein C [Xigris™] worldwide evaluation in severe sepsis
• PSYCLOPS: psychosis and clozapine in Parkinson's disease
• PTAMD: prophylactic treatment of AMD [age-related macular degeneration]
• PURSUIT: platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using Integrilin™ therapy
• QoLITY: quality of life trial hypertension; MT Desk glossary
• QUIET: quinapril [Accupril™] ischemic event trial
• RACECAR: restenosis and clinical evaluation in coronary arteries; sponsor: Medtronic
• RALES: randomized Aldactone® (spironolactone) evaluation study for congestive heart failure; MT Desk glossary
• RAPID:
  • radiation after PTA is done; sponsor: Radiance Medical Systems [RDX™ coronary radiation delivery catheter]
  • rapid-acting Parkinson('s) drug
• RAPPORT: ReoPro® and primary PTCA organization and ramdomized trial
• RAVEL: randomized study with the sirolimus-eluting Bx Velocity™ balloon-expandable stent [Cypher™]; sponsor: Cordis
• REACH:
  • rehabilitation among women with coronary heart disease
  • research on endothelin antagonism in chronic heart failure; MT Desk glossary
• REACT: rapid early action for coronary treatment; University of Minnesota and JAMA 2000;283:3223-3229 [July 5, 2000]
• ReALIZe: research to assess the long-term impact of Zomaril™
• RECIFE: reduction of cholesterol in ischemia and function of the endothelium
• REDHOT: rapid emergency department heart failure outpatient trial [Trial to evaluate clinical utility of the Triage® BNP test in assessing effectiveness of therapy in the management of CHF.]
• REGRESS: regression growth evaluation statin study
• REIN: ramipril efficacy in nephropathy
• REMATCH: randomized evaluation of mechanical assistance therapy as an alternative in congestive heart failure; MT Desk glossary
• RENAAL: reduction in endpoints in patients with non–insulin-dependent diabetes mellitus with the angiotensin II antagonist losartan
• RENAISSANCE: randomized Enbrel® North American strategy to study antagonism of cytokines
• RESPECT: risk evaluation and stroke prevention in the elderly - cerivastatin trial; MT Desk glossary
• RESTOR: R stent™ efficacy and safety trial Orbus; sponsor: Orbus Medical Technologies
• RESTORE: randomized efficacy study of tirofiban for outcomes and restenosis; MT Desk glossary
• REVERSAL: reversal of atherosclerosis with Lipitor™
• REVERT: reversal of ventricular remodeling with Toprol-XL®; MT Desk glossary
• RHYTHM: resynchronization for hemodynamic treatment for heart failure management; sponsor: St. Jude Medical [Epic™ HF ]
• RID-HD: riluzole dosing in Huntington disease
• RITZ-2: randomized intravenous tezosentan
• ROSTER: rotational atherectomy versus balloon angioplasty for diffuse in-stent restenosis
• RUTH: raloxifene use for the heart; MT Desk glossary
• SADHAT: sertraline (Zoloft®) antidepressant heart attack trial
• SADHART: sertraline antidepressant heart attack randomized trial
• SAFE: safety after fifty evaluation
• SAFER: saphenous vein graft angioplasty free of emboli randomized trial; MT Desk glossary entry
• SAFE-T: sotalol and amiodarone atrial fibrillation effectiveness trial
• SAGE: study assessing goals in the elderly
• SAPPHIRE: systolic and pulse pressure hemodynamic improvement by restoring elasticity; sponsor: Alteon Inc. [ALT-711]
• SARECCO: stent or angioplasty after recanalization of chronic coronary occlusions
• S.A.V.S.: Synercid® as an alternative to vancomycin in staph[ylococcal infections] SAVS
• SCD-HeFT or SCDHeFT: sudden cardiac death/heart failure trial
• SCRIP: study of cardiovascular risk intervention by pharmacists
• SCRIPPS: Scripps coronary radiation to inhibit proliferation post stenting
• SEAL: simple and effective arterial closure study; MT Desk glossary
• SEARCH: study of effectiveness of additional reductions of cholesterol and homocysteine
• SECURE: study to evaluate carotid ultrasound changes in patients treated with ramipril [Altace®] and vitamin E
• SELECT: selenium and vitamin E cancer prevention trial; description
• SELENA: safety of estrogens in lupus erythematosus national assessment
• SHARP: subcutaneous heparin and angioplasty restenosis prevention
• SHELTER: stenting of high risk patients extracranial lesions trial with emboli removal; MT Desk glossary
• SHEP: systolic hypertension in the elderly program
• SHIPS: study of a home intervention post stroke
• SHOCK: should we emergently revascularize occluded coronaries for cardiogenic shock
• SHOW: study of health outcomes in weight loss
• SICCO: stenting in chronic coronary occlusion
• SIESTA: snooze-induced excitation of sympathetic triggered activity
• SILCAAT: study of interleukin-2 (IL-2) in people with low CD4+ T-cell counts on active anti-HIV therapy; Chiron Corporation
• SILENT: sonotherapy for in-lesion elimination of neointimal tissue; sponsor: PharmaSonics Inc.; also see MT Desk glossary
• SILVER: systolic hypertension interaction with left ventricular remodeling; sponsor: Alteon Inc. [ALT-711]
• SIRIUS: a multicenter randomized double-blind study of the sirolimus-coated Bx Velocity™ stent [referred to as Cypher™ sirolimus-eluting stent] in the treatment of patients with de novo coronary artery lesions; sponsor: Cordis
• SIROCCO: sirolimus-coated Cordis S.M.A.R.T™ nitinol self-expanding stent in the treatment of obstructive superficial femoral artery disease
• SMART:
  • second manifestations of arterial disease
  • serum markers acute myocardial infarction and rapid treatment
  • strategies for the management of antiretroviral therapy
  • study of medicine versus angioplasty reperfusion trial
  • study of Microstent's ability to limit restenosis trial
  • study of monoclonal antibody radioimmunotherapy; MT Desk glossary
  • Synercid® microbiological assessment of resistance trends; MT Desk glossary
• SMILE: survival of myocardial infarction long-term evaluation
• SNAP: study of nitroglycerin and chest pain
• SPAF: stroke prevention in atrial fibrillation
• SPEED: strategies for patency enhancement in the emergency department
• SPORT: spine patient ooutcomes research trial
  stent implantation post rotational atherectomy trial
• SPORTIF-V: stroke prevention using oral thrombin inhibition in atrial fibrillation - V [5th series of SPORTIF trials]; MT Desk glossary
• SOLVD: studies of left ventricular dysfunction
• SONIA: stroke outcomes and neuroimaging of intracranial atherosclerosis
• SONORA : safety of Neoral outcomes in rheumatoid arthritis
• S.O.N.O.R.A.^SM: study of new onset rheumatoid arthritis; sponsor: Knoll Pharmaceutical Company
• SoS: stent or surgery
• SPARCL: stroke prevention by aggressive reduction in cholesterol levels
• SPICE: study of protease inhibitor combination in Europe; MT Desk glossary
• SPLASH: sonotherapy prevention of late arterial in-stent hyperplasia; sponsor: PharmaSonics, Inc.; also see MT Desk glossary
• SPS3: stroke prevention of small subcortical strokes
• SSITT: Swiss-Spanish intermittent trial
• SSYLVIA: stenting in symptomatic atherosclerotic lesions of vertebral and intracranial arteries
• STAR: study of tamoxifen and raloxifene; MT Desk glossary
• STARS: standard treatment with activase to reverse stroke
• START:
  • saruplase and taprostene acute reocclusion trial
  • St. Thomas' atherosclerosis regression trial
  • study of thrombolytic therapy with additional response following taprostene
  • stent versus angioplasty restenosis trial
  • stent versus directional coronary atherectomy randomized trial
  • stents and radiation therapy; MT Desk glossary
  • selection of thymidine analog regimen therapy; MT Desk glossary
• STAT: stroke treatment with ancrod trial
• Stent PAMI: stent primary angioplasty for myocardial infarction
• STEP-BD: systematic treatment enhancement program for bipolar disorder; study description
• STICH: surgical treatment for intracerebral hemorrhage
• STOP: sonotherapy for the treatment of peripheral vascular disease; sponsor: PharmaSonics, Inc.
• STOP-DUB: surgical treatments outcomes project for dysfunctional uterine bleeding
• STOP-Hypertension: Swedish trial in old patients with hypertension; MT Desk glossary
• STRATAS: study to determine Rotablator® and transluminal angioplasty strategy
• STRENGTH; STRENGTH II: statin response examined by genetic HAP™ markers; sponsor: Genaissance Pharmaceuticals
• STRESS: stent restenosis study
• STRETCH: symptom, tolerability, response to exercise trial of candesartan cilexetil [Atacand™] in heart failure
• STRIDE: sitaxsentan to relieve impaired exercise in pulmonary hypertension
• SUDEP: sudden unexpected death in epilepsy
• SWEDIC: Sweden diastolic carvedilol
• SWIFT: should we intervene following thrombolysis
• SWING: sound waves inhibit neointimal growth; sponsor: PharmaSonics Inc.; also see MT Desk glossary
• SWISS: siblings with ischemic stroke study
• SWOG: Southwest Oncology Group [an adult cancer clinical trials organization]; SWOG protocols by indication
• SYMPHONY: sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes ; MT Desk glossary
• SYNERGY: superior yield of the new strategy of enoxaparin, revascularization, and glycoprotein IIb/IIIa inhibitors
• TACT : trial to assess chelation therapy [EDTA chelation therapy for coronary artery disease]; sponsor: National Institutes of Health (NIH)
• TACTICS:
  • thrombolysis and counterpulsation to improve cardiogenic shock survival
  • treat angina with Aggrastat® and determine costs of therapy with invasive or conservative strategies [TIMI-18]
• TAIST: tinzaparin in acute ischemic stroke trial
• TARGET: do tirofiban [Aggrastat®] and ReoPro give similar efficacy outcomes trial
• TCAS: temperature control during aneurysm surgery
• TexCAPS: Texas coronary atherosclerosis prevention study
• TeqCES: Tequin® clinical experience study
• TheraP: TheraSource™ Pd-103 for prevention of restenosis; sponsor: Theragenics Corporation [TheraSource™ intravascular brachytherapy system]
• TIGER-PA: tirofiban given in the emergency room before primary angioplasty
• TIME: trial of invasive vs. medical therapy in elderly patients with chronic CAD
• TIMI:
  • thrombolysis in myocardial infarction; MT Desk glossary
  • thrombin inhibition in myocardial infarction
• TNT: treating to new targets
• TOAT: the open artery trial
• TONE: trial of nonpharmacologic interventions in the elderly
• TOP: treatment of osteoporosis with PTH [ALX1-11, a recombinant parathyroid hormone (PTH) formulation]; sponsor: NPS Pharmaceuticals
• TOPIC: tobramycin once-daily prescribing in cystic fibrosis
• TRACE:
  • trandolapril cardiac evaluation study
  • trial of genetic assessment in breast cancer
• TRAFFIC: therapeutic angiogenesis with FGF-2 (fibroblast growth factor) for intermittent claudication; sponsor: Chiron Corporation
• TRANSCEND: telmisartan [Micardis®] randomized assessment study in ace intolerant subjects with cardiovascular disease
• TREAT: tranilast restenosis following angioplasty trial
• TREND: trial on reversing endothelial dysfunction
• TROPHY: trial for preventing hypertension; MT Desk glossary
• TRUST: Tenax® for the prevention of restenosis and acute thrombotic complications. A useful stent trial [Tenax-XR, a silicon carbide-coated stent]; sponsor: Biotronik, Inc.
• TTT4CNV: transpupillary thermotherapy for choroidal neovascularization
• TURBO: the ultrasound removal of blood clots in vein grafts; Angiosonics
• TUSS: tuberculosis ultraviolet shelter study
• UK-HEART: United Kingdom heart failure evaluation and assessment of risk trial
• UKPDS: United Kingdom perspective diabetes study
• UNAIDS PETRA: United Nations programme on HIV/AIDS perinatal transmission trial
• VA-HIT: Veterans Administration HDL intervention trial
• Val-HeFT: valsartan heart failure trial; MT Desk glossary
• VALIANT:
  • valsartan in acute myocardial infarction trial; MT Desk glossary
  • Vascular Architects femoropopliteal suboptimal angioplasty aSpire™ stent trial; sponsor: Vascular Architects
• VALUE: valsartan antihypertensive long-term use evaluation; MT Desk glossary
• VANILA: ventricular arrhythmia needing intravenous lidocaine/amiodarone
• VANQWISH: Veterans Affairs non–Q-wave infarction strategies in hospital
• VERT: vertebral efficacy with risedronate therapy; risedronate (Actonel®)
• VICTORY: elective and acute stenting of coronary arteries on Express™ [coronary stent] system; sponsor: Boston Scientific
• VIGOR: Vioxx® gastrointestinal outcomes research
• VINTAGE MI: vascular interaction with age in myocardial infarction
• VISION: vascular intervention study with ionizing radiation; sponsor: Guidant Corp. [Galileo™ intravascular radiotherapy system]
• VISP : vitamin intervention for stroke prevention
• VITATOPS: vitamins to prevent stroke
• VIVA: VEGF (vascular endothelial growth factor) in ischemia for vascular angiogenesis
• VMAC: vasodilation in the management of acute congestive heart failure; MT Desk glossary
• WARCEF: warfarin-aspirin reduced cardiac ejection fraction
• WARIS-II : warfarin-aspirin reinfarction study
• WARSS: warfarin aspirin recurrent stroke study
• WASID: warfarin-asprin symptomatic intracranial disease study
• WATCH:
  • warfarin & antiplatelet therapy in chronic CHF
  • women atorvastatin trial on cholesterol
• WAVE: women's angiographic vitamins and estrogen trial
• WEARIT: wearable cardioverter-defibrillator investigational trial
• WIHS: women's interagency HIV study
• WINS: women's intervention nutrition study
• WISE: women's ischemia syndrome evaluation; MT Desk glossary
• WIZARD: weekly intervention with Zithromax® against atherosclerosis and related disorders
• Women's HOPE: Women's health, osteoporosis, progestin, and estrogen study
• WRIST: Washington radiation for in-stent restenosis trial
• XISHF: xamoterol in severe heart failure
• X-TRACT: X-Sizer™ for treatment of thrombus and atherosclerosis in coronary interventions trial
• ZEUS: Zomaril™ efficacy/utility and safety; MT Desk glossary
• ZIPP: Zoladex® (goserelin acetate implant) in premenopausal patients

View clinical trial acronyms A to L .